Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Busulfan (BU) will be given at a dose of 0.8 mg/kg IV q 6 hrs. BU doses will be modified based upon pharmacokinetics data to maintain steady state levels of 600-900 ng/dl. Seizure prophylaxis with levetiracetam should begin prior to the 1st dose of BU and stoped 24 hrs after the last dose of BU. Melphalan will be given at a dose of 60 mg/m2 I.V. over 15-20 min per Pediatric SCT Standards of Practice Manual.

Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.

EWINGS SARCOMA

Rabbit anti-thymocyte globulin

Busulfan

Melphalan

Fludarabine

Cyclophosphamide

University of Louisville

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

A Phase I Study to Examine the Toxicity of Allogeneneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewings

This will be assessed by safety labs and close monitoring from the study staff.

Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma

Sarcoma

Soft Tissue Sarcoma

Locally Advanced Sarcoma

Unresectable Sarcoma

Metastatic Sarcoma

Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid

University of Iowa Hospitals and Clinics

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Dose-limiting toxicities per CTCAE 4.0; grade 4 hematologic toxicity; grade 3 or 4 hepatotoxicity.

Mohammed M Milhem

Clinical Associate Professor

Genentech, Inc.

Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.

High Grade Sarcoma

Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).

Valproic Acid

Columbia University Medical Center

Adjuvant Valproate for High Grade Sarcomas

A Pilot Study of Adjuvant Valproate for Patients With High Grade Sarcomas

The primary end point will be evaluated by the 3-year recurrence rate of lower grade sarcoma histopathologically (or more well differentiated as compared to the primary tumor) amongst those who experience 3-year sarcoma recurrence.

seizures/sarkooma

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

Adjuvant Valproate for High Grade Sarcomas

Täydellisin lääketieteellinen tietokanta tieteen tukemana